About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Npm1tm1Gsva
targeted mutation 1, George S Vassiliou
MGI:5004857
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Npm1tm1Gsva/Npm1+
TgTn(pb-sb-GrOnc)#aGsva/0
Tg(Mx1-cre)1Cgn/0 		involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:5007701
cn2
 		Npm1tm1Gsva/Npm1tm1Gsva
Dppa3tm1(cre)Peli/Dppa3+ 		involves: 129S5/SvEvBrd * 129S7/SvEvBrd MGI:5004901
cn3
 		Npm1tm1Gsva/Npm1+
Tg(Mx1-cre)1Cgn/0 		involves: C57BL/6 * CBA MGI:5004900


Genotype
MGI:5007701
cn1
Allelic
Composition		 Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Npm1tm1Gsva/Npm1+
TgTn(pb-sb-GrOnc)#aGsva/0
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(CAG-hsb5)Nki mutation (0 available); any Gt(ROSA)26Sor mutation (944 available)
Npm1tm1Gsva mutation (0 available); any Npm1 mutation (33 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
TgTn(pb-sb-GrOnc)#aGsva mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:172071 )
• mean survival of pIpC-treated mice is 99 days compared with 150 days for Gt(Rosa)26Sortm4(CAG-hsb5)Nki Gt(Rosa)26Sor+ Tg(Mx1-cre)1Cgn TgTn(pb-sb-GrOnc)#aGsva control mice

neoplasm
increased leukemia incidence ( J:172071 )
• all mice develop aggressive leukemia and/or lymphoma within a year of pIpC induction
increased lymphoma incidence ( J:172071 )
• all mice develop aggressive leukemia and/or lymphoma within a year of pIpC induction
• however, pIpC-treated mice do not develop T cell lymphomas unlike in control mice
increased B cell derived lymphoma incidence ( J:172071 )
• in some pIpC-treated mice
increased hemangiosarcoma incidence ( J:172071 )
• angiosarcoma in some pIpC-treated mice




Genotype
MGI:5004901
cn2
Allelic
Composition		 Npm1tm1Gsva/Npm1tm1Gsva
Dppa3tm1(cre)Peli/Dppa3+
Genetic
Background		 involves: 129S5/SvEvBrd * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dppa3tm1(cre)Peli mutation (0 available); any Dppa3 mutation (22 available)
Npm1tm1Gsva mutation (0 available); any Npm1 mutation (33 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
embryonic lethality, complete penetrance ( J:172071 )
• no mice are present at E8.0




Genotype
MGI:5004900
cn3
Allelic
Composition		 Npm1tm1Gsva/Npm1+
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Npm1tm1Gsva mutation (0 available); any Npm1 mutation (33 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:172071 )
• due to acute myeloid leukemia, survival of pIpC-treated mice is 617 days compared with 769 days for wild-type mice

hematopoietic system
enlarged spleen ( J:172071 )
• in pIpC-treated mice
increased spleen weight ( J:172071 )
• in pIpC-treated mice
abnormal common myeloid progenitor cell morphology ( J:172071 )
• with serial replating, cells from pIpC-treated mice exhibit increased myeloid progenitor colony formation on methylcellulose compared with cells from wild-type mice
increased mean corpuscular volume ( J:172071 )
• in pIpC-treated mice
increased mean platelet volume ( J:172071 )
• in pIpC-treated mice
decreased B cell number ( J:172071 )
• pIpC-treated mice exhibit a decrease in late B cells (B220+ CD19+) compared with wild-type mice
increased leukocyte cell number ( J:172071 )
• in pIpC-treated mice
increased granulocyte number ( J:172071 )
• in pIpC-treated mice

neoplasm
increased acute promyelocytic leukemia incidence ( J:172071 )
• acute myeloid leukemia with maturation in pIpC-treated mice
increased B cell derived lymphoma incidence ( J:172071 )
• in 6 of 13 pIpC-treated mice

liver/biliary system
enlarged liver ( J:172071 )
• in pIpC-treated mice
increased liver weight ( J:172071 )
• in pIpC-treated mice

immune system
enlarged spleen ( J:172071 )
• in pIpC-treated mice
increased spleen weight ( J:172071 )
• in pIpC-treated mice
decreased B cell number ( J:172071 )
• pIpC-treated mice exhibit a decrease in late B cells (B220+ CD19+) compared with wild-type mice
increased leukocyte cell number ( J:172071 )
• in pIpC-treated mice
increased granulocyte number ( J:172071 )
• in pIpC-treated mice

growth/size/body
enlarged liver ( J:172071 )
• in pIpC-treated mice
increased liver weight ( J:172071 )
• in pIpC-treated mice
enlarged spleen ( J:172071 )
• in pIpC-treated mice
increased spleen weight ( J:172071 )
• in pIpC-treated mice




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/30/2024
MGI 6.23 		The Jackson Laboratory